Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

Bayer’s BAYRY wholly owned subsidiary, BlueRock Therapeutics, announced that the first patient in the phase I/IIa CLARICO study has received OpCT-001, an investigational iPSC-derived cell therapy, ...

The drug will now progress to pivotal Phase III trials after demonstrating trends towards a disease-modifying impact.

Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations ...

– SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim ...

A new study by the University of California, Davis, shows how cells work together to avoid a sudden drop in blood sugar.

A team has gained new insights into lithium-sulphur pouch cells at the BAMline of BESSY II. A new picture emerges of processes that limit the performance and lifespan of this industrially relevant ...